From the Femidom to the Maputo Declaration, the SRH field is littered with disappointed developers and failed initiatives.
(Don’t feel bad: the Femidom is a female condom and the Maputo Declaration committed African countries to spending reasonable amounts on reproductive health).
Good research can keep your idea or product away from the scrap heap.
Baird’s CMC and its partners have run qualitative research in SRH for most of the world’s top ten pharma companies, for activists, for global NGOs, for Foundations and donors, for multilateral organisations and national governments.
We have looked at stakeholders, the policy environment, drivers and barriers in coming to market, pricing, intellectual property and the best ways to encourage South-South R&D collaboration … among many other subjects.
What we’ve done
- Assessing how HIV opinion leaders (medical, community and policy) in Africa and South Asia acquire information, which sources they found most credible and which were accessible, for a major pharmaceutical company
- Work on donor attitudes to funding specific healthcare interventions in low- and middle-income countries for the Bill & Melinda Gates Foundation, Johns Hopkins Bloomberg School of Public Health, Merck & Co Inc, the Shell Foundation and PATH (these were individual projects on various interventions)
- Understanding why patients with advanced hepatitis C disease are referred for certain types of treatment and not for others in six European markets (in cooperation with RAND)
- Assessing likely reactions from opinion leaders and stakeholders to new data on the relative cost efficiency of funding voluntary family planning programmes as a way of averting future climate change, for the William & Flora Hewlett Foundation
- Using market research to forecast the likely future direction of European policy on overseas development assistance, in particular for spending on family planning, HIV and hepatitis